Canagliflozin does not increase fracture risk in diabetes patients

02 Jan 2019


Canagliflozin treatment does not increase the risk of fractures in type-2 diabetes patients, according to research published in Annals of Internal Medicine.

MedicalXpress


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story